Compare iShares MSCI Japan ETF (EWJ) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Mesoblast Limited — how do they compare? iShares MSCI Japan ETF trades at $91.99, while Mesoblast Limited trades at $19.22 (market cap $2.31B). Which is the better fit depends on your goals.
| EWJ | MESO | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $96.97 | $20.96 |
52-Week Low | $71.81 | $11.35 |
Market Cap | — | $2.31B |
Enterprise Value | — | $2.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $91.98, down 2.03% on the day. The technical outlook is bullish based on moving averages, with oscillators neutral. Key support lies at $92-$93 and resistance at $94-$95. Recent news highlights Japan's market dynamics, including currency intervention risks and pension fund shifts.
The ETF offers exposure to Japanese equities amid a weakening yen and potential government support. Risks include yen volatility and economic sensitivity. Analyst sentiment is mixed, with technical strength offset by currency and macroeconomic uncertainties.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
